A Phase II Study of Tazemetostat (EPZ-6438) (IND # 138671) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma
Principal Investigator
Ramez Eskander, MD
Status
Closed to Accrual
Date Opened To Accrual
January 25 2019
Date Closed to Accrual
June 15 2022
Disease Site
Gynecologic [GY]
Ovarian
Phase
II
Developmental Therapeutics
No
Primary Objective
To assess the clinical activity (overall response rate) of tazemetostat in patients with recurrent or persistent endometrioid or clear cell ovarian carcinoma, and patients with recurrent or persistent endometrioid endometrial adenocarcinoma.
Patient Population
Women with pathologically proven diagnosis of recurrent or persistent ovarian clear cell carcinoma with an ARID1A mutation per NGS.
Primary or recurrent ovarian tumors must be at least 50% endometrioid or clear cell morphology.
All patients must have measurable disease, and have had at least 1, but no more than 3, prior cytotoxic regimens for management of primary disease.
Target Accrual
86
Patient Study Webpage
There is no available patient study webpage available for this trial at this time.